Jonathan P S Knisely
Overview
Explore the profile of Jonathan P S Knisely including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Layng S, Betsock A, Mansouri A, Komiya T, Miccio J, Mahase S, et al.
Discov Oncol
. 2025 Feb;
16(1):157.
PMID: 39934444
Metastatic intracranial progression drastically impacts prognosis, therapeutic considerations and quality of life. The increasing incidence of lung cancer patients developing brain metastases (BM) parallels the incorporation of more effective systemic...
2.
Perlow H, Raleigh D, Wang T, Pollom E, Milano M, Breen W, et al.
Int J Radiat Oncol Biol Phys
. 2024 Dec;
PMID: 39701546
Purpose: Meningiomas are the most common primary intracranial tumor. Somatostatin receptor 2 is almost universally expressed in meningioma tissue. For patients who require adjuvant radiation, somatostatin receptor based (68)Ga-DOTATATE positron...
3.
Tom M, Nagpal S, Palmer J, Breen W, Pollom E, Lehrer E, et al.
Radiother Oncol
. 2024 Nov;
202:110640.
PMID: 39557126
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2...
4.
Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, et al.
Eur J Radiol
. 2024 Oct;
181:111791.
PMID: 39423781
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases...
5.
Yadav D, Dutruel S, ODwyer E, Ricaurte-Fajardo A, Upadhyay R, Palmer J, et al.
Eur J Radiol
. 2024 Sep;
180:111711.
PMID: 39226675
Purpose: Theranostic approaches combining prostate-specific membrane antigen (PSMA)-PET/CT or PET/MRI with PSMA-targeted radionuclide therapy have improved clinical outcomes in patients with prostate cancer (PCa) especially metastatic castrate resistant prostate cancer....
6.
Biological Insights and Radiation-Immuno-Oncology Developments in Primary and Secondary Brain Tumors
Gregucci F, Beal K, Knisely J, Pagnini P, Fiorentino A, Bonzano E, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893165
Malignant central nervous system (CNS) cancers include a group of heterogeneous dis-eases characterized by a relative resistance to treatments and distinguished as either primary tumors arising in the CNS or...
7.
Kim J, Chang S, Haghdel A, Ramakrishna R, Pannullo S, Schwartz T, et al.
AJNR Am J Neuroradiol
. 2024 Apr;
45(6):773-780.
PMID: 38604734
Background And Purpose: WHO grade 3 meningiomas are rare and poorly understood and have a higher propensity for recurrence, metastasis, and worsened clinical outcomes compared with lower-grade meningiomas. The purpose...
8.
Ivanidze J, Chang S, Haghdel A, Kim J, Roy Choudhury A, Wu A, et al.
Neuro Oncol
. 2024 Mar;
26(8):1526-1535.
PMID: 38553990
Background: Our purpose was to determine the utility of [68Ga]-DOTATATE PET/MRI in meningioma response assessment following radiosurgery. Methods: Patients with meningioma prospectively underwent postoperative DOTATATE PET/MRI. Co-registered PET and gadolinium-enhanced...
9.
Perlow H, Nalin A, Handley D, Gokun Y, Blakaj D, Beyer S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Oct;
118(4):979-985.
PMID: 37871886
Purpose: The current standard for meningioma treatment planning involves magnetic resonance imaging-based guidance. Somatostatin receptor ligands such as Ga-DOTATATE are being explored for meningioma treatment planning due to near-universal expression...
10.
Kim S, Chang S, Dobri G, Strauss S, Lin E, Zavaletta V, et al.
Pituitary
. 2023 Jun;
26(4):419-428.
PMID: 37285059
Purpose: The pituitary gland has the fourth highest physiologic avidity of [68 Ga]-DOTATATE. In order to guide our understanding of [68 Ga]-DOTATATE PET in clinical contexts, accurate characterization of the...